Navigation Links
Oramed Pharmaceuticals to Present at the 4th Annual Drug Delivery & Formulation Summit in Berlin
Date:2/18/2013

JERUSALEM, February 18, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral delivery systems, announced today that Dr. Ehud Arbit , Oramed's Director of Research & Development, will be presenting at the 4th Annual Drug Delivery and Formulation Summit in Berlin, Germany. The presentation, titled "Formulating Protein Therapies for Oral Delivery and Understanding Implications on Treatment and Patient Compliance: An Industry Case Study," will be given on Tuesday, February 19th, at the biologics session from 9:55-10:35am. The summit venue is the Maritim Pro Arte Hotel.

The Drug Delivery & Formulation Summit sources and presents leading global case studies from such top-tier pharmaceutical companies as Pfizer, GSK, Novartis, Merck and Eli Lilly. The Summit provides a forum for pharmaceutical industry experts to present, discuss and debate scientific and strategic advancements in pharmaceutical development.

For more information, please visit the summit's website: http://www.ddfevent.com

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently approaching Phase 2 clinical trials under U.S. IND, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit  http://www.oramed.com.

The company's fact sheet, the content of which is not part of this press release, can be viewed here.

Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss our oral insulin and oral exenatide candidates approaching Phase 2 clinical trials under U.S. IND and 2a clinical trials, respectively. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Cell: +972-54-792-4438
Office: +972-2-566-0001       
Email: aviva@oramed.com


'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Shares of Oramed Pharmaceuticals Are Approved for Listing on the Nasdaq Capital Market
2. Oramed Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on February 7th
3. Oramed Pharmaceuticals Completes $5.6 Million Funding to Advance Clinical Trials
4. Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
5. Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand
6. Oramed Pharmaceuticals to Present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference; Tel Aviv, Israel, 2012
7. Neurim Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of Piromelatine for the Treatment of Insomnia
8. Cumberland Pharmaceuticals To Announce 2012 Year End Financial Results On February 28, 2013
9. Coyote Pharmaceuticals Initiates GMP Manufacturing Process for CNS-102 Following Successful Pre-IND Meeting
10. Founder of Nestle-Acquired Company Joins Prismic Pharmaceuticals
11. RQx Pharmaceuticals and Genentech Enter Drug Discovery Collaboration to Develop Novel Drug Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... 23, 2017 ArisGlobal, a leading ... announces agClinical 3.3, the latest version of its comprehensive ... science organizations to confidently and efficiently meet new compliance ... the electronic trial master file so that compliance is ... ...
(Date:1/23/2017)... , Jan. 23, 2017 Endo International ... Trade Commission (FTC) today filed a joint motion in ... California seeking the entry of ... Order resolves all disputes between the FTC and Endo ... in connection with its Opana® ER and Lidoderm® products.  ...
(Date:1/23/2017)... CLARA, Calif. , Jan. 23, 2017 /PRNewswire/ ... protection market, Frost & Sullivan recognizes Ansell, a ... Global Frost & Sullivan Company of the Year ... customer-centric approach, and a wide global footprint have ... in the hand protection market. The Company,s established ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... , ... “Choosing Wisdom-Solomon’s Proverbs Reclaimed”: an inspiring collection ... adultery, anger, and common sense. , “Choosing Wisdom-Solomon’s Proverbs Reclaimed” is the ... In September of 1983, they flew to Haiti to focus on missions work. ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... use to improve the connection with God. “Spiritual Vitamins: A Spiritual Energy Booster” ... Published by Christian Faith Publishing, Mathai Yohannan’s new book engages the mind and ...
(Date:1/24/2017)... ... January 24, 2017 , ... “The Octagon of Spiritual Balances”: ... Spiritual Balances” is the creation of published author, Pastor Bernard J. Weathers, pastor of ... a bachelor degree in religious education and a master degree in theology. , ““The ...
(Date:1/24/2017)... ... January 24, 2017 , ... Attention women ... article suggests that autologous fat grafting—taking one’s own fat and putting it ... breast implants. , Cosmetic Surgeon and Medical Director of MilfordMD Cosmetic Dermatology ...
(Date:1/24/2017)... ... January 23, 2017 , ... ... on Friday, January 20, with the bipartisan original co-sponsorship of nearly one-quarter of ... January 12. The National Association of Chain Drug Stores (NACDS) strongly backs the ...
Breaking Medicine News(10 mins):